Objective: The Malaysian NCVD-ACS (National Cardiovascular Disease Database-Acute Coronary Syndrome) registry attempts to determine the incidence and demographic profile of patients with ACS and to identify high risk group among them. It provides a comprehensive view to assess treatment strategies and adherence to existing guidelines for ACS patients; which can help in future development. It also aims to facilitate research using this database.

Methods: The study included patients with ST-segment elevation myocardial infarction (STEMI), non-ST-elevation myocardial infarction (NSTEMI) and unstable angina (UA) admitted to 11 participating sites in Malaysia from 1st January 2006 to 31st December 2006. The data were analyzed in terms of characteristics, clinical presentation, treatment, in-hospital outcome and 30-day outcome.

Results: A total of 3422 patients were enrolled, with male to female ratio of 3:1, mean age of 59 ± 12 years and mean BMI of 25.8 ± 4.4 kg/m². Among total study population, 96% had at least one established cardiovascular risk factor. In STEMI population, 70% received fibrinolytic therapy and 8% proceeded for primary percutaneous coronary intervention (PCI). Mean door-toneedle time for fibrinolytic therapy was 103 ± 143 min. Medical management was conducted for 86% of NSTEMI and 91% UA patients, with intervention for 14% and 9% respectively. The overall in-hospital mortality and 30-day mortality were 7% and 8% respectively.

Conclusion: In our NCVD-ACS registry, when compared with other registries, the subjects were much younger at presentation and had higher prevalence of established cardiovascular risk factors, indicating the importance of primary prevention programme. Majority of the patients were managed medically, with low rates of cardiac interventions, the factor being driven largely by availability of resources. Mean door-to-needle time was much higher than the recommended guidelines, an issue that needs attention. The results indicate many opportunities for improvement of in-hospital and 30-day mortality.